Engineering Biology Innovation
Carbometrics aim to help people with diabetes live more normal and longer lives. They are using their proprietary Biomimetic Glucose Binding Molecule (GBM) to develop a new glucose sensor chemistry that will enable market-leading Continuous Glucose Monitors (CGM).
CDotBio is developing novel carbon-based technology for rapid crop adaptations to address the challenges of climate change and food security. It is founded on the discovery that carbon nanoparticles (Carbon Dots) can enter plant cells and has led to the use of these particles to deliver genetic material, simplifying gene editing (GE) and non-GM approaches to creating novel plant traits.
Dyador originates from a collaboration at the University of Bristol between leading academics in Cellular, Molecular and Chemical Sciences. Its objective is to employ nanoparticle technologies for significantly improved bacterial identification.
Folium Science creates alternatives to the need to use antibiotics, by providing precise bacterial control for agricultural production. It has developed a unique and patented technology called Guided Biotics that selectively removes unwanted bacteria. This will help to reduce the need to use antibiotics in farmed animals, support the health of plants, and lead to improved food productivity.
Glaia is using revolutionary 'sugar-dots' technology, developed at the University of Bristol, to allow plants to harvest light more efficiently and facilitate the processes involved in biomass production, resulting in increased crop yields. With this technology, Glaia aims to effectively help ensure food security in the future as well as reduce the carbon footprint of agricultural food production.
Halo Therapeutics aim to solve the urgent need for at-home therapeutic treatment for COVID-19 by providing safe, pan coronavirus antivirals which COVID-19 patients can apply by themselves.
Hone Bio (formerly Cytoseek) aim to use Artificial Membrane Binding Protein (AMBP) technology to deliver the potential of the next generation of cell therapies, with a focus on treating solid tumours. Hone Bio are developing AMBPs that can provide homing, immunomodulation, and/or hypoxia resistance functionality.
Imophoron is a pre-clinical stage company whose researchers have engineered a novel synthetic protein scaffold named ADDomer™, for creating highly immunogenic vaccine candidates. Proof of concept data for two highly infectious diseases has demonstrated potential to prevent disease and transmission. Unlike most vaccines, their Chikungunya vaccine candidate can be produced and stored without refrigeration.
Photoclear is creating sustainable solutions for wastewater biological treatment. Their bioaugmenting additives accelerate bacterial metabolism and improve separation in wastewater treatment, enhancing processes like activated sludge and anaerobic digestion. These reusable, plug-and-play additives are compatible with any bacterial treatment tank, boosting efficiency and biogas production, while creating a circular system where residual sludge can be recycled to produce more additives.
Purespring are developing a proprietary platform and novel treatments focused on targeting the podocyte, a cell type vital to kidney function and health. Purespring's therapies will target rare monogenic diseases, as well as much more prevalent common forms of kidney disease. It is the first gene therapy platform to specifically target kidney diseases.
Scarlet Therapeutics is developing a pioneering platform that generates novel red blood cell-based therapeutics (tRBCs) to treat a wide range of diseases. Born out of more than a decade of research at the University of Bristol and the learnings from the RESTORE clinical study, Scarlet’s technologies aim to address efficacy and manufacturing issues faced by others in the field by ensuring a high level of therapeutic proteins inside the tRBCs, enabling more efficacious and thus effective therapies and improving the manufacturing by being able to generate the tRBCs from cell lines rather than from donated stem cells.
Zentraxa use bioengineering to produce peptides, specifically 'BioBetters', with predictable properties that are tailored to purpose. The spin-out has secured £500k investment to commercialise their proprietary technological platform, Zentide, to produce biological adhesives for the heathcare sector.